Nuvo Research Announces New Listing of Synera® Patent in FDA Orange Book
News Dec 27, 2012
Nuvo Research Inc. has announced that the United States Patent Office has granted the reinstatement of Patent No. 6,465,709 related to Synera® Patch (Synera Patent).
Nuvo has listed the Synera Patent in the U.S. Food and Drug Administration's (FDA) Orange Book.
The Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant seeking FDA approval for a generic version of Synera prior to expiration of the patent to notify Nuvo of its ANDA filing before it can obtain FDA approval.
"We are very pleased that we have received additional patent protection for Synera Patch in the U.S.," said Tina Loucaides, Nuvo's Vice-President and General Counsel.
Loucaides continued, "The listing of this patent in the FDA Orange Book provides us with significantly more years of protection and will allow us to better explore expanded indications for this unique topical local anesthetic patch."
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018